What Are Clear Cell and Endometrioid Ovarian Cancers?

Clear cell and endometrioid ovarian carcinomas are distinct, specialized subtypes of ovarian cancer. While they share some initial treatments with the more common high-grade serous ovarian cancer (HGSOC), they have unique origins and, in many cases, entirely different genetic drivers. Most notably, clear cell (OCCC) and endometrioid (EnOC) tumors are strongly linked to a history of endometriosis ^[1][2].

Understanding these differences is crucial because it can influence your prognosis and determine which targeted therapies or clinical trials might be most effective for your specific care plan.

The Link to Endometriosis

Endometriosis is a condition where tissue similar to the lining of the uterus grows outside the uterus, sometimes forming cysts on the ovaries called endometriomas. Research shows a strong link between endometriosis and the development of clear cell and endometrioid ovarian cancers ^[1][2].

While it is important to remember that the vast majority of people with endometriosis will never develop ovarian cancer, when these specific cancer subtypes do occur, they often arise from the malignant transformation of these misplaced endometrial cells ^[1]. Because endometriosis can cause pain or other symptoms that prompt medical imaging, these cancers are often caught at an earlier stage than other types.

Additionally, because endometrioid ovarian cancer shares origins with uterine tissue, it is sometimes found alongside a simultaneous cancer in the uterus. Your care team will likely evaluate your uterus for this reason ^[2].

Different Genetic Drivers

If you have read about ovarian cancer, you have likely heard about BRCA1, BRCA2, and TP53 mutations. While those are the primary genetic drivers for high-grade serous ovarian cancer, clear cell and low-grade endometrioid cancers typically operate on a different “genetic engine” ^[3][4]. (Note: High-grade endometrioid cancers often behave more like high-grade serous cancers and may still have TP53 mutations).

Instead of BRCA mutations, clear cell and low-grade endometrioid subtypes frequently feature mutations in:

• ARID1A: A gene that helps regulate how DNA is packaged and read. When this gene is mutated, cells lose an important control mechanism against cancer ^[3][4].
• PIK3CA: A gene involved in cellular growth signaling. Mutations here can cause cells to grow and divide uncontrollably ^[3].

Because they often lack BRCA mutations, drugs known as PARP inhibitors—which are highly effective in BRCA-mutated cancers—might not be the most effective targeted option for these types, unless other specific genetic features are present ^[3].

How Does This Alter Treatment?

Initial Surgery and Chemotherapy

The first steps in treating clear cell and endometrioid ovarian cancers are usually the same as for other types: thorough surgical removal of the tumor, often followed by platinum-based chemotherapy ^[5].

Endometrioid tumors often respond well to these standard treatments. However, clear cell carcinomas, in particular, can sometimes be more resistant to standard chemotherapy drugs ^[6][7]. If your clear cell tumor is resistant to chemotherapy, try not to panic—this is exactly why biomarker testing and clinical trials exist. Identifying your tumor’s unique biology provides entirely different paths forward when standard chemotherapy isn’t enough ^[8][9].

Prognosis and Staging

Because these subtypes are frequently diagnosed at an early stage (Stage I or II), initial surgery can be highly effective, and survival rates for early-stage disease are generally very good ^[5].

If clear cell carcinoma is diagnosed at an advanced stage, it can have a more challenging prognosis compared to advanced high-grade serous cancer due to that chemotherapy resistance ^[7]. But this is precisely why researchers are rapidly developing the targeted therapies mentioned below, offering actionable hope and new avenues of treatment ^[10].

Eligibility for Targeted Therapies and Clinical Trials

Because clear cell and endometrioid tumors have distinct biology, oncologists are increasingly looking beyond standard chemotherapy to find treatments tailored to their specific genetic profile ^[8]. This makes tumor biomarker testing (genomic profiling) essential. Your doctor will typically test the tissue already removed during your surgery—you usually do not need an extra procedure for this.

Your genetic profile can open doors to specific treatments and clinical trials:

• Targeting ARID1A: Researchers are heavily investigating synthetic lethal strategies. This simply means exploiting the tumor’s missing ARID1A gene by blocking the backup pathways it relies on to survive, effectively cutting off its lifeline ^[3][4].
• PI3K/AKT Inhibitors: Because of PIK3CA mutations, clinical trials are testing drugs that interrupt these overactive growth signals ^[3].
• Immunotherapy and Lynch Syndrome: Endometrioid tumors, in particular, may possess molecular features (like mismatch repair defects) that make them responsive to immunotherapy, which helps your own immune system fight the cancer ^[11]. These mismatch repair defects are sometimes tied to a hereditary condition called Lynch syndrome. Finding this out is incredibly valuable, as it can prompt hereditary genetic testing and guide cancer prevention for both you and your family ^[11].
• Anti-angiogenic Drugs: Medications like bevacizumab, which starve tumors by blocking new blood vessel growth, have shown benefits in treating advanced or recurrent clear cell carcinomas ^[10][9].

By understanding the unique biology of your tumor, you and your medical team can better navigate the landscape of standard treatments, targeted therapies, and clinical trials.